Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Type: Journal article
Title: Angiogenesis in multiple myeloma: Implications in myeloma therapy
Author: Martin, S.
To, L.
Horvath, N.
Zannettino, A.
Citation: Cancer Reviews: Asia-Pacific, 2004; 2(2):119-129
Publisher: World Scientific Publishing Co. Pte. Ltd.
Issue Date: 2004
ISSN: 0219-8363
Statement of
Sally K Martin, Luen Bik To, Noemi Horvath, Andrew CW Zannettino
Abstract: Angiogenesis, or the formation of new blood vessels from pre-existing vasculature through sprouting or invagination, is a complex process involving many factors. The role of angiogenesis in the progression of cancer has been extensively explored, and it is now well established that elevated levels of angiogenesis in many solid tumors correlates with poor prognosis. Similarly, recent evidence suggests that blood vessel formation plays a pivotal role in the progression of hematological malignancies, including the plasma cell malignancy, multiple myeloma. Several studies have shown that bone marrow angiogenesis is significantly increased in patients with active multiple myeloma and is indicative of poor prognosis. Malignant myeloma cells are known to secrete several angiogenic factors which may play a role in the increased angiogenesis in the bone marrow of myeloma patients. Anti-angiogenic therapy with thalidomide is now considered to be a standard therapy for advanced myeloma patients and a number of new anti-angiogenic therapies are currently undergoing clinical trials for use in this disease.
Keywords: Angiogenesis; Multiple myeloma; Thalidomide; Plasma cell; Therapy; Angiogenic factors
Rights: Copyright status unknown
RMID: 0020042312
DOI: 10.1142/S0219836304000470
Appears in Collections:Medicine publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.